SOCS6 is a suppressor of cytokine signaling protein that functions as a negative regulator of receptor tyrosine kinase signaling 1. It acts as a component of an E3 ubiquitin-protein ligase complex that mediates ubiquitination and proteasomal degradation of target proteins, including the KIT receptor and JAK2/STAT3 pathway components 2. SOCS6 exerts tumor-suppressive effects through multiple mechanisms: it induces apoptosis by targeting anti-apoptotic proteins like Bcl2 3, suppresses angiogenesis 3, and negatively regulates inflammatory signaling by promoting p65 ubiquitination and degradation 4. Clinically, SOCS6 is downregulated across multiple cancers including colorectal, gastric, lung, and hepatocellular carcinomas 1. In colorectal cancer specifically, reduced SOCS6 expression serves as a diagnostic biomarker and correlates with poor prognosis 5, with cancer-derived exosomal miR-106a-5p suppressing SOCS6 to promote liver metastasis 2. SOCS6 downregulation also associates with disease progression in hepatitis B-related liver disease 6 and diabetic retinopathy, where decreased serum SOCS6 correlates with disease severity and increased inflammatory cytokines 7. Pharmacological histone deacetylase inhibitors like valproic acid can reactivate SOCS6 expression to induce cancer cell apoptosis 8.